TABLE 3.
Treatment Patterns and Axitinib Dosing Patterns
| Characteristic | Total (N = 1,175) | Second Line (n = 659) | Third Line (n = 326) | > Fourth Line (n = 190) |
|---|---|---|---|---|
| Duration of axitinib therapy, days | ||||
| Mean (SD) | 168.6 (±148.4) | 172.3 (±150.6) | 169.2 (±146.9) | 154.6 (± 142.8) |
| Median (range) | 115 (7-688) | 114 (8-688) | 122 (7-644) | 111(10-642) |
| Therapy received directly before axitinib, n (%) | ||||
| Sunitinib | 446 (38) | 368 (56) | 51 (16) | 27 (14) |
| Everolimus | 259 (22) | 78 (12) | 142 (44) | 39 (21) |
| Pazopanib | 244 (21) | 106 (16) | 65 (20) | 73 (38) |
| Temsirolimus | 83 (7) | 56 (8) | 17 (5) | 10 (5) |
| Sorafenib | 44 (4) | 19 (3) | 15 (5) | 10 (5) |
| Bevacizumab | 31 (3) | 12 (2) | 13 (4) | 6 (3) |
| Other | 68 (6) | 20 (3) | 23 (7) | 25 (13) |
| Axitinib daily dose,a mg | ||||
| Mean (SD) | 10.3 (3) | 10.3 (3) | 10.5 (3) | 10.2 (3) |
| Median (range) | 10.0 (2.0-31.5) | 10.0 (2.0-31.5) | 10.0 (3.5-21.4) | 10.0 (2.0-20.0) |
| Axitinib dose modifications,a n (%) | ||||
| No change | 789 (67) | 445 (68) | 213 (66) | 131 (69) |
| Decrease | 161 (14) | 90 (14) | 43 (13) | 28 (15) |
| Increase | 141 (12) | 79 (12) | 44 (14) | 18 (10) |
| Increase then decrease | 83 (7) | 45 (7) | 25 (8) | 13 (7) |
aA total of 1,174 patients were evaluated for axitinib dosing patterns; 1 patient whose titration patterns could not be determined and did not follow expected clinical patterns was excluded.
SD = standard deviation.